Immnophenotypic markers in AML: Difference between revisions
From haematologyetc.co.uk
No edit summary |
No edit summary |
||
| Line 12: | Line 12: | ||
! colspan="2" style = "font-size:100%; color:black"| '''Table:''' Marker patterns that allow definite diagnosis of acute myeloid leukaemia; | ! colspan="2" style = "font-size:100%; color:black"| '''Table:''' Marker patterns that allow definite diagnosis of acute myeloid leukaemia; | ||
|- | |- | ||
|colspan="2" style = "font-size:90%; color:black; background:#ddeee1"|'''Pattern 1:'''</br>A myeloid '''lineage-defining''' marker pattern is present</br>'''and'''</br>No lineage-defining markers of T or B cells are present | |colspan="2" style = "font-size:90%; color:black; background:#ddeee1"|'''Pattern 1:'''</br>A myeloid '''lineage-defining''' marker pattern is present</br>'''and'''</br>No lineage-defining markers of T or B cells are present. | ||
|- | |- | ||
|colspan="1" style = "font-size:90%; color:black; width:15%;" |'''[[MPO]]''' | |colspan="1" style = "font-size:90%; color:black; width:15%;" |'''[[MPO]]''' | ||
Revision as of 15:33, 20 December 2023
| Table: Marker patterns that allow definite diagnosis of acute myeloid leukaemia; | |
|---|---|
| Pattern 1: A myeloid lineage-defining marker pattern is present and No lineage-defining markers of T or B cells are present. | |
| MPO | MPO is the only "lineage-defining" marker of AML. MPO is expressed in around 80% of cases of AML and in the absence of any other lineage defining features detection of MPO expression allows a diagnosis of AML to be made (see notes). |
| Other markers: In the context of a proven AML diagnosis a number of markers may be expressed that reflect the primitive nature of the cells. Some of these are more frequently associated with lymphoid disorders, but providing other criteria for AML are met they should simply be considered to show "primitivness". | |
| CD38 | Variable expression in AML cases (around 20%) compared with higher expression on lymphoid blasts (particularly T-ALL). CD38 may identify leukaemia initiating cells and is a potential therapeutic target. |
| HLA-DR | Expressed in around 70-80% of AML cases, but also frequently expressed in ALL. The most valuable aspect of HLA-DR is the absent or weak expression in APL when compared with reactive myeloid cells. |
| TDT | TdT is more often associated with ALL, but the expression by around 20% of AML cases is well recognised, particularly in more primitive forms of the disease. |
| CD7 | Regarded as a pan-T-cell marker expressed throughout T cell development, CD7 is also expressed frequently as an "aberrant" marker in AML where it is best regarded as a marker of their primitive nature |